Reuters logo
BRIEF-Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska pharmaceutical
2017年2月27日 / 下午1点02分 / 7 个月前

BRIEF-Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska pharmaceutical

Feb 27 (Reuters) - Pieris Pharmaceuticals Inc

* Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska Pharmaceutical

* Pieris Pharmaceuticals Inc - co will receive an immediate option payment of $2.75 million usd from Aska

* Pieris Pharmaceuticals Inc - a Phase 1 study conducted in healthy volunteers demonstrated that a single dose of PRS-080 was well tolerated

* Pieris Pharmaceuticals Inc - Pieris may also receive double-digit royalties on net sales of PRS-080 up to mid- to high-teens

* Pieris Pharmaceuticals Inc - PRS-060, anticipated to begin a first-in-human study around middle of 2017

* Pieris Pharmaceuticals Inc - PRS-343 scheduled to enter a first-in patient trial in first half of 2017

* Pieris Pharmaceuticals - should Aska exercise option, Pieris would be eligible for over $80 million usd in combined option exercise fee and milestones Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below